- Home
- MHUA vs RLMD Comparison
MHUA vs RLMD Comparison
Compare MHUA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- RLMD
- Stock Information
- Founded
- MHUA 1990
- RLMD 2004
- Country
- MHUA China
- RLMD United States
- Employees
- MHUA N/A
- RLMD N/A
- Industry
- MHUA Medical Specialities
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- RLMD Health Care
- Exchange
- MHUA Nasdaq
- RLMD Nasdaq
- Market Cap
- MHUA 9.6M
- RLMD 11.5M
- IPO Year
- MHUA 2022
- RLMD N/A
- Fundamental
- Price
- MHUA $0.36
- RLMD $0.30
- Analyst Decision
- MHUA
- RLMD Hold
- Analyst Count
- MHUA 0
- RLMD 4
- Target Price
- MHUA N/A
- RLMD $4.25
- AVG Volume (30 Days)
- MHUA 222.1K
- RLMD 2.1M
- Earning Date
- MHUA 09-20-2024
- RLMD 03-18-2025
- Dividend Yield
- MHUA N/A
- RLMD N/A
- EPS Growth
- MHUA 29.93
- RLMD N/A
- EPS
- MHUA 0.37
- RLMD N/A
- Revenue
- MHUA $94,252,537.00
- RLMD N/A
- Revenue This Year
- MHUA N/A
- RLMD N/A
- Revenue Next Year
- MHUA N/A
- RLMD N/A
- P/E Ratio
- MHUA $0.98
- RLMD N/A
- Revenue Growth
- MHUA N/A
- RLMD N/A
- 52 Week Low
- MHUA $0.25
- RLMD $0.28
- 52 Week High
- MHUA $1.47
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- MHUA 56.71
- RLMD 30.81
- Support Level
- MHUA $0.33
- RLMD $0.28
- Resistance Level
- MHUA $0.37
- RLMD $0.36
- Average True Range (ATR)
- MHUA 0.02
- RLMD 0.04
- MACD
- MHUA 0.01
- RLMD 0.02
- Stochastic Oscillator
- MHUA 83.17
- RLMD 7.21
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.